{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:16:01Z","timestamp":1790345761634,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004863","name":"Zhejiang Chinese Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ23H270012"],"award-info":[{"award-number":["LQ23H270012"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["2025JKZKTS11"],"award-info":[{"award-number":["2025JKZKTS11"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.phrs.2026.108239","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:49:03Z","timestamp":1778244543000},"page":"108239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Overcoming breast cancer resistance through targeted protein degradation and next generation chimeras"],"prefix":"10.1016","volume":"229","author":[{"given":"Xinyao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1024-2234","authenticated-orcid":false,"given":"Jiawen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2026.108239_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.phrs.2026.108239_bib2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/CCO.0000000000000972","article-title":"Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer","volume":"35","author":"Grinshpun","year":"2023","journal-title":"Curr. Opin. Oncol."},{"issue":"21","key":"10.1016\/j.phrs.2026.108239_bib3","doi-asserted-by":"crossref","first-page":"19010","DOI":"10.1021\/acs.jmedchem.4c01521","article-title":"Discovery of ERD-1233 as a potent and orally efficacious estrogen receptor PROTAC degrader for the treatment of ER+ human breast cancer","volume":"67","author":"Acharyya","year":"2024","journal-title":"J. Med Chem."},{"issue":"16","key":"10.1016\/j.phrs.2026.108239_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163996","article-title":"Overcoming resistance to HER2-directed therapies in breast cancer","volume":"14","author":"Schlam","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/1078-0432.CCR-25-3040","article-title":"Real-world outcomes of elacestrant in ER+, HER2-, ESR1-mutant metastatic breast cancer","volume":"32","author":"Rugo","year":"2026","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.phrs.2026.108239_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur. J. Med Chem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108239_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.phrs.2026.108239_bib9","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.phrs.2026.108239_bib10","article-title":"The peptide PROTAC modality: a new strategy for drug discovery","volume":"6","author":"Zhu","year":"2025","journal-title":"MedComm (2020)"},{"issue":"22","key":"10.1016\/j.phrs.2026.108239_bib11","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. & Med. Chem. Lett."},{"issue":"6241","key":"10.1016\/j.phrs.2026.108239_bib12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.phrs.2026.108239_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"9, 2025","key":"10.1016\/j.phrs.2026.108239_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-cancerbio-061824-105806","article-title":"Development of PROTAC degrader drugs for cancer","volume":"9","author":"Vetma","year":"2025","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"26","key":"10.1016\/j.phrs.2026.108239_bib16","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in bruton's tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun. Biol."},{"issue":"4_ement","key":"10.1016\/j.phrs.2026.108239_bib18","doi-asserted-by":"crossref","first-page":"PD13-08","DOI":"10.1158\/1538-7445.SABCS21-PD13-08","article-title":"Abstract PD13-08: first-in-human safety and activity of ARV-471, a novel PROTAC\u00ae estrogen receptor degrader, in ER+\/HER2- locally advanced or metastatic breast cancer","volume":"82","author":"Hamilton","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108239_bib19","first-page":"23","article-title":"24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+\/Human Epidermal Growth Factor Receptor 2 (HER2)\u2013 Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1\/2 Study","volume":"37","author":"Hurvitz","year":"2023","journal-title":"Miami Breast Cancer Conf. \u00ae Abstr. Suppl."},{"issue":"6","key":"10.1016\/j.phrs.2026.108239_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.phrs.2026.108239_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.611","article-title":"Targeted protein degradation: design considerations for PROTAC development","volume":"2","author":"Tran","year":"2022","journal-title":"Curr. Protoc."},{"issue":"3","key":"10.1016\/j.phrs.2026.108239_bib22","article-title":"PROTACs: a novel strategy for cancer drug discovery and development","volume":"4","author":"Han","year":"2023","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.phrs.2026.108239_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114775","article-title":"Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers","volume":"244","author":"Hu","year":"2022","journal-title":"Eur. J. Med Chem."},{"issue":"203","key":"10.1016\/j.phrs.2026.108239_bib24","doi-asserted-by":"crossref","DOI":"10.3791\/65718","article-title":"The development and application of biophysical assays for evaluating ternary complex formation induced by proteolysis targeting chimeras (PROTACS)","author":"Jiang","year":"2024","journal-title":"J. Vis. Exp."},{"issue":"7559","key":"10.1016\/j.phrs.2026.108239_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2026.108239_bib26","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.phrs.2026.108239_bib27","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2026.108239_bib28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"19","key":"10.1016\/j.phrs.2026.108239_bib29","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40364-025-00826-7","article-title":"Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation","volume":"13","author":"Zhao","year":"2025","journal-title":"Biomark. Res"},{"issue":"6336","key":"10.1016\/j.phrs.2026.108239_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.phrs.2026.108239_bib32","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acschembio.0c00348","article-title":"A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL","volume":"15","author":"Tong","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108239_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103781","article-title":"Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress","volume":"85","author":"Chen","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.phrs.2026.108239_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102552","article-title":"Design and characterization of a heterobifunctional degrader of KEAP1","volume":"59","author":"Chen","year":"2023","journal-title":"Redox Biol."},{"issue":"6414","key":"10.1016\/j.phrs.2026.108239_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.phrs.2026.108239_bib36","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1212\/01.WNL.0000146196.01316.A2","article-title":"A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation","volume":"63","author":"Higgins","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108239_bib37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13238-018-0586-8","article-title":"Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and Itch","volume":"10","author":"Aki","year":"2018","journal-title":"Protein & Cell"},{"issue":"11","key":"10.1016\/j.phrs.2026.108239_bib38","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2026.108239_bib39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.phrs.2026.108239_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsptsci.2c00100","article-title":"Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of zeste homolog 2","volume":"5","author":"Dale","year":"2022","journal-title":"ACS Pharm. Transl. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib41","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1038\/s41598-025-92494-8","article-title":"Targeted degradation of CDK4\/6 by LA-CB1 inhibits EMT and suppresses tumor growth in orthotopic breast cancer","volume":"15","author":"He","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib42","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2026.108239_bib43","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010100","article-title":"From PROTAC to TPD: advances and opportunities in targeted protein degradation","volume":"17","author":"Wang","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/emboj\/19.1.94","article-title":"Recognition of the polyubiquitin proteolytic signal","volume":"19","author":"Thrower","year":"2000","journal-title":"Embo J."},{"key":"10.1016\/j.phrs.2026.108239_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2022.08.048","article-title":"Accelerating PROTAC drug discovery: establishing a relationship between ubiquitination and target protein degradation","volume":"628","author":"Gross","year":"2022","journal-title":"Biochem Biophys. Res Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108239_bib48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annu Rev. Biochem"},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib49","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41467-019-13906-8","article-title":"The proteasome 19S cap and its ubiquitin receptors provide a versatile recognition platform for substrates","volume":"11","author":"Martinez-Fonts","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108239_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.molcel.2009.01.014","article-title":"Nonproteolytic functions of ubiquitin in cell signaling","volume":"33","author":"Chen","year":"2009","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.phrs.2026.108239_bib51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrm3659","article-title":"Push back to respond better: regulatory inhibition of the DNA double-strand break response","volume":"14","author":"Panier","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108239_bib52","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2011.01.035","article-title":"The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2","volume":"144","author":"Wickliffe","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2026.108239_bib53","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2014.03.037","article-title":"Enhanced protein degradation by branched ubiquitin chains","volume":"157","author":"Meyer","year":"2014","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.phrs.2026.108239_bib54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ncb3358","article-title":"The increasing complexity of the ubiquitin code","volume":"18","author":"Yau","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2026.108239_bib55","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40958","article-title":"UBE2G1 governs the destruction of cereblon neomorphic substrates","volume":"7","author":"Lu","year":"2018","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.phrs.2026.108239_bib56","first-page":"327","article-title":"An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions","volume":"50","author":"Guzzetti","year":"2023","journal-title":"J. Pharm. Pharm."},{"issue":"16","key":"10.1016\/j.phrs.2026.108239_bib57","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.phrs.2026.108239_bib58","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1042\/BCJ20243018","article-title":"Methods to accelerate PROTAC drug discovery","volume":"482","author":"Osman","year":"2025","journal-title":"Biochem J."},{"issue":"16","key":"10.1016\/j.phrs.2026.108239_bib59","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/ja311795d","article-title":"A comprehensive mathematical model for three-body binding equilibria","volume":"135","author":"Douglass","year":"2013","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib60","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.108239_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115329","article-title":"A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer","volume":"206","author":"Li","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"32","key":"10.1016\/j.phrs.2026.108239_bib62","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108239_bib63","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","article-title":"Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets","volume":"9","author":"Qian","year":"2023","journal-title":"Cell Death Discov."},{"issue":"39","key":"10.1016\/j.phrs.2026.108239_bib65","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/s41388-024-03121-1","article-title":"BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression","volume":"43","author":"Kong","year":"2024","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.phrs.2026.108239_bib66","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol."},{"issue":"7586","key":"10.1016\/j.phrs.2026.108239_bib67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.phrs.2026.108239_bib68","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy","volume":"12","author":"Koppula","year":"2021","journal-title":"Protein Cell"},{"issue":"3","key":"10.1016\/j.phrs.2026.108239_bib69","first-page":"1060","article-title":"The functional role of the EZH2 gene in controlling breast cancer stem cells","volume":"24","author":"Wang","year":"2019","journal-title":"J. buon"},{"key":"10.1016\/j.phrs.2026.108239_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116154","article-title":"Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2","volume":"267","author":"Velez","year":"2024","journal-title":"Eur. J. Med Chem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108239_bib71","doi-asserted-by":"crossref","first-page":"315","DOI":"10.26599\/NBE.2025.9290128","article-title":"Emerging strategies in smart nano-PROTAC for stimuli-responsive protein degradation and precision cancer therapy","volume":"17","author":"Weng","year":"2025","journal-title":"Nano Biomed. Eng."},{"issue":"12","key":"10.1016\/j.phrs.2026.108239_bib72","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical property determinants of oral absorption for PROTAC protein degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J. Med Chem."},{"issue":"11","key":"10.1016\/j.phrs.2026.108239_bib73","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.7150\/ijbs.83026","article-title":"Emerging pharmacotherapeutic strategies to overcome undruggable proteins in cancer","volume":"19","author":"Lu","year":"2023","journal-title":"Int J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2026.108239_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030685","article-title":"Targeting CDK4\/6 for Anticancer Therapy","volume":"10","author":"Qi","year":"2022","journal-title":"Biomedicines"},{"issue":"7_ement","key":"10.1016\/j.phrs.2026.108239_bib75","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1538-7445.AM2023-3875","article-title":"Abstract 3875: evaluation of resistance mechanisms to ARV471, an ER-targeted PROTAC","volume":"83","author":"Friel","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108239_bib76","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1039\/D4MD00961D","article-title":"Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance","volume":"16","author":"Peng","year":"2025","journal-title":"RSC Med Chem."},{"issue":"18","key":"10.1016\/j.phrs.2026.108239_bib77","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res"},{"issue":"7_ement","key":"10.1016\/j.phrs.2026.108239_bib78","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1538-7445.AM2023-432","article-title":"Abstract 432: mechanisms of acquired resistance to ARV-471, a novel PROTAC\u00ae estrogen receptor degrader","volume":"83","author":"Teh","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib79","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2026.108239_bib80","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.phrs.2026.108239_bib81","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-0716-1665-9_17","article-title":"PHOTACs enable optical control of protein degradation","volume":"2365","author":"Reynders","year":"2021","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib82","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib83","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1021\/jacs.2c10177","article-title":"Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors","volume":"145","author":"Yang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"28","key":"10.1016\/j.phrs.2026.108239_bib84","doi-asserted-by":"crossref","first-page":"8741","DOI":"10.1021\/acs.nanolett.4c02287","article-title":"Ultrasound-activated PROTAC prodrugs overcome immunosuppression to actuate efficient deep-tissue sono-immunotherapy in orthotopic pancreatic tumor mouse models","volume":"24","author":"Liu","year":"2024","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.phrs.2026.108239_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-024-01364-y","article-title":"Targeted degradation of membrane and extracellular proteins with LYTACs","volume":"46","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin."},{"issue":"5","key":"10.1016\/j.phrs.2026.108239_bib86","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"issue":"7781","key":"10.1016\/j.phrs.2026.108239_bib87","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108239_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"7820","key":"10.1016\/j.phrs.2026.108239_bib89","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:07:04Z","timestamp":1783123624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":89,"alternative-id":["S1043661826001544"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108239","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming breast cancer resistance through targeted protein degradation and next generation chimeras","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108239"}}